1. Heim
  2. Products
  3. Aspaveli
  4. Mechanism of action
Aspaveli - 0 - Aspaveli - NO

Aspaveli is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.1

Mechanism of action for Aspaveli

Aspaveli is the first and only C3i for the treatment of PNH.1

Aspaveli targets C3 to address both IVH and C3-mediated EVH1,3,4

Aspaveli targets C3 to address both IVH and C3-mediated EVH

 

Learn more about Aspaveli’s mechanism of action

References

1. Aspaveli (pegcetacoplan) Summary of Product Characteristics 08/2024. 2. Hillmen P, Szer J, Weitz IC, et al. N Engl J Med. 2021;384:1028–1037. 3. Risitano AM, Marotta S, Ricci P, et al. Front Immunol. 2019;10:1157. 4. Merle NS, Noe R, Halbwachs-Mecarelli L, et al. Front Immunol. 2015;6:257.  5. Risitano AM and Peffault de Latour R. BJH. 2022;196:288–303.

PP-20367
Other sites
expand_less